Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Cancer Vaccine Eliminates Tumors

A cancer vaccine is about to enter human trials on lymphoma patients at Stanford University that could potentially eliminate tumors. Unfortunately, tumors are able to neutralize the immune system and continue to grow and spread throughout the body. Inhibitory signals on immune cells (T cells) are delivered by cytotoxic T lymphocyte–associated protein 4 (CTLA4) and programmed cell death protein 1 (PD1) by interaction with their respective ligands expressed on cancer cells. However, T cells also express stimulatory receptors including the tumor necrosis factor receptor (TNFR) superfamily. Previous attempts for cancer treatment have targeted the checkpoints in the antitumor immune response and to stimulate the activation pathways of the tumor-infiltrating effector T cells.

A recent report demonstrated the eradication of tumors by local immunotherapy. Mice were injected locally into the tumor with the combination of TLR9 ligand and anti-OX40 antibody and were monitored for the regression of tumors, for the occurrence of new tumors, and for their survival. By treating the tumors, T cells could be triggered that already recognize the cancer cells so they are primed to target other tumors. Researchers have shown that this treatment is highly effective in mice and will move on to human trials. This new cancer treatment can therefore potentially prime the immune system to eradicate tumors throughout the body. This treatment would bypass the need to identify tumor specific targets and could potentially work for many different cancer types.

For more information: http://stm.sciencemag.org/content/10/426/eaan4488.full

Enzo offers a wide variety of products for your Cancer and TNF research needs. Our platform provides a range of small molecules, antibodies, and proteins. Our CD134 (h):Fc (h) (rec) (OX40) is produced in HEK 293 cells with high activity and low endotoxin levels. Our SCREEN-WELL® Cancer Library is a collection of 275 compounds that can be used for cancer inhibitor screening and assay development.

Never miss a new TechNote!

Receive our TechNotes as soon as they are published.


 
comments powered by Disqus

Follow Us!

 

Related Products

CD134 (human):Fc (human), (recombinant) 

Produced in HEK 293 cells. The cysteine-rich region of human CD134 (OX40) (aa 29-214) is fused to the Fc portion of human IgG1., ≥95% (SDS-PAGE), ELISA | Print as PDF
 
ALX-522-022-C050 50 µg 417.00 USD
Do you need bulk/larger quantities?
 

PD-1 (human), (recombinant) 

Produced in HEK cells. Extracellular domain of PD-1 (aa 25-167) containing a 5’-His-tag, V5 epitope tag spacer, and a FLAG-tag., ≥90% (SDS-PAGE) | Print as PDF
 
ENZ-PRT190-0050 50 µg 307.00 USD
Do you need bulk/larger quantities?
 

PD-L1 (human), (recombinant) 

Produced in HEK cells. Human PD-L1 (aa 19-239) is fused at the N-terminus to a His-tag and FLAG®-tag., ≥90% (SDS-PAGE) | Print as PDF
 
ENZ-PRT223-0100 100 µg 480.00 USD
Do you need bulk/larger quantities?
 

SCREEN-WELL® Cancer Library 

Essential standards for cancer inhibitor screening
HTS | Print as PDF
 
ENZ-LIB102-0100 1 Library 100 µl/well Inquire for pricing
Do you need bulk/larger quantities?
 

MEGACD40L® Protein (soluble) (human), (recombinant) 

High activity, high purity CD40L protein for co-stimulatory activation of an immune response
Produced in CHO cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag., ≥90% (SDS-PAGE) | Print as PDF
 
ALX-522-110-C010 10 µg 499.00 USD
Do you need bulk/larger quantities?
 

LAG-3 (human):Fc (human), (recombinant) 

Produced in CHO cells. The sequence coding for the 4 extracellular Ig-like domains of human LAG-3 (D1-D4) is fused to the Fc portion of human IgG1., ≥99% (SDS-PAGE), ELISA, Flow Cytometry | Print as PDF
 
ALX-522-078-C050 50 µg 508.00 USD
Do you need bulk/larger quantities?
 

LAG-3 (mouse):Fc (mouse), (recombinant) 

Produced in CHO cells. The sequence coding for the 4 extracellular Ig-like domains of mouse LAG-3 (D1-D4) is fused to the Fc portion of mouse IgG2a (hinge-CH2-CH3)., ≥95% (SDS-PAGE), Flow Cytometry | Print as PDF
 
ALX-522-099-C050 50 µg 508.00 USD
Do you need bulk/larger quantities?
 

TLR9 polyclonal antibody 

ICC, WB | Print as PDF
 
ADI-905-730-100 100 µg 373.00 USD
Do you need bulk/larger quantities?
 

Toll-like receptor 9 (mouse) polyclonal antibody 

ICC, IHC (PS), WB | Print as PDF
 
ALX-210-637-C200 200 µg 297.00 USD
Do you need bulk/larger quantities?
 

CD134L (soluble) (human), (recombinant) 

Produced in HEK 293 cells. The extracellular domain of human CD134L (OX40L) (aa 52-183) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag., ELISA | Print as PDF
 
ALX-522-023-C010 10 µg 278.00 USD
 
ALX-522-023-3010 3x10 µg SuperPack 522.00 USD
Do you need bulk/larger quantities?
 

TNF-α (soluble) (human), (recombinant) 

Produced in E. coli. The extracellular domain of human TNF-α (tumor necrosis factor-α) (aa 85-223) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag., ≥95% (SDS-PAGE), ELISA | Print as PDF
 
ALX-522-008-C050 50 µg 328.00 USD
Do you need bulk/larger quantities?
 

Control:Fc fusion protein (human), (recombinant) 

Negative control for Fc chimeric proteins
Produced in HEK 293 cells. The extracellular domain of mutated hThy-1, hThy-1 (RLE) (aa 20-130), is fused to the Fc portion of human IgG1. The integrin binding sequence RLD of hThy-1 has been changed to RLE abolishing the binding of integrins., ≥90% (SDS-PAGE) | Print as PDF
 
ALX-203-004-C050 50 µg 413.00 USD
Do you need bulk/larger quantities?
 

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2018 Enzo Life Sciences, Inc.,